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Abstract 
 
Background: We investigate the likely impact of vaccines on the prevalence and 
morbidity of Chlamydia trachomatis infections in heterosexual populations.  
 
Methods: An individual-based mathematical model of C. trachomatis transmission is 
developed and linked to the infection course in Chlamydia-infected individuals. The 
model describes the impact of a vaccine through its affect on the chlamydial load 
required to infect susceptible individuals (the ‘critical load’) and the chlamydial load 
in, and subsequent infectiousness of, infected individuals. The model is calibrated 
using behavioral, biological and clinical data.  
 
Results: A fully protective chlamydial vaccine administered prior to sexual debut can 
theoretically eliminate C. trachomatis epidemics within 20 years. Partially effective 
vaccines can still greatly reduce Chlamydia incidence. Vaccines should primarily aim 
to increase the critical load in susceptible individuals and secondarily decrease the 
peak load and/or the duration of infection in vaccinated individuals who become 
infected. Vaccinating both genders has a beneficial impact on Chlamydia-related 
morbidity but targeting women is more effective than targeting men.  
 
Conclusions: Our findings can be used in laboratory settings to evaluate vaccine 
candidates in animal models, by regulatory bodies in the promotion of candidates for 
clinical trials, and by public health authorities in deciding upon optimal intervention 
strategies.  
 
Keywords: Chlamydia trachomatis, vaccines, mathematical modeling.  
                                                                                                                                        3 
Introduction 
 
The incidence of sexually transmitted Chlamydia trachomatis is increasing in many 
countries [1-3]. This is of important public health and economic concern as C. 
trachomatis infections are a leading cause of pelvic inflammatory disease (PID), 
ectopic pregnancy, and infertility in women [4] and male infertility [5]. Public health 
interventions have been ineffective thus far [6] and may even have increased 
Chlamydia incidence [7]. Over the long term an effective vaccine will be the most 
successful intervention against Chlamydia epidemics [8, 9].  
 
Although chlamydial vaccine research has been conducted for more than 35 years, 
progress has been modest [8]. Apart from some early, unsuccessful attempts in 
humans [8, 10], all vaccine work has been in animal models.  Recently, efforts have 
been made to identify chlamydial antigens that elicit protective immunity against the 
multiple serovars (D-K) of C. trachomatis responsible for genital tract infections  
[11]. In the mouse model, immunization with many of these antigens, as well as with 
the commonly used major outer membrane protein (MOMP) reduces infection 
duration and the amount of Chlamydia shed. However, sterilizing immunity has not 
been achieved. Defining immunization routes that target immunity to the reproductive 
tract and adjuvants that elicit both a strong Th1 response and a mucosal antibody 
response required to control infections is essential for a successful vaccine.  The 
protection provided by experimental vaccines against live challenge is usually modest 
although the level required in animal models to be useful in human studies is never 
discussed.   
 
Currently, the population-level impact of vaccines on Chlamydia epidemiology is 
unknown.  Understanding the ability of a vaccine to control the incidence, prevalence, 
and morbidity of Chlamydia infections in the general population is important in the 
development, evaluation, regulation, and implementation of candidate vaccines. To 
predict the impact of potential Chlamydia vaccines we develop a mathematical model 
that simulates transmission in a heterosexual population by linking the within-host 
biology of susceptible and Chlamydia-infected individuals to their sexual behavior 
and partnership dynamics. Our model tracks the infection time course, disease 
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progression, and dynamic infectiousness of infected individuals and the transmission 
to others. We investigate the population-level impact of vaccines that: (i) protect 
uninfected people by raising the infectiousness threshold required to transmit an 
infection; (ii) alter the natural course of infection in Chlamydia-infected people by 
changing the growth rate, peak chlamydial load, or duration of infection; (iii) increase 
the duration of immunity post-infection due to treatment or natural clearance; and (iv) 
provide sterilizing immunity but only for a finite duration. We also explore the likely 
effect of public health interventions based on various gender-specific vaccine 
coverage levels. 
 
Methods  
 
We develop an individual-based transmission model that tracks 20,000 sexually-
active heterosexual people, with a 1:1 ratio of men to women. Our model is calibrated 
to biological, behavioral, and epidemiological data from general heterosexual 
populations such that the median pre-vaccine prevalence of Chlamydia is 4-5%.  
Model parameters are listed in Table 1 and a detailed description of the model is 
presented in the Supplementary Material.  
 
In our model, individuals enter the population upon sexual debut as others age out, 
keeping the population constant. Homogenous sexual mixing is assumed with the 
formation and break-up of short-term (casual) and long-term (regular) partnerships 
dynamically modeled. Concurrent partnerships are restricted to a core group of people 
(5% of the population). Sexual behavior dynamics (including intercourse frequency 
and condom use) are simulated according to probabilistically-inferred rates defined in 
Table 1.  
 
For each infected person, the chlamydial load (the number of IFUs per ml of mucosal 
cervicovaginal secretion) is tracked over time. Between individuals the IFU growth 
and decay rates vary while the peak IFU load and inoculum size are fixed (unless the 
infected person was previously vaccinated) (Table 1). Infections are naturally cleared 
when the load falls below 10 IFU, leading to mean infection duration of ~14 months. 
We assume that  75% of infected individuals are asymptomatic with a low 
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background rate of testing and treatment [6, 12] and that most symptomatic 
individuals seek treatment within a short time (see Table 1). We assume that 20% of 
infections in women ascend to the upper genital tract [13] and that PID can uniformly 
occur at any time during a woman’s infection. This results in a PID prevalence of 
~0.4-0.5% (agreeing with empirical estimates [14]) and a realistic distribution for the 
lifetime number of PID episodes with ~15% of women having an episode of PID in 
their lifetime and a small proportion of women having three or more episodes. We 
assume short-term immunity following a naturally cleared infection with successfully 
treated individuals having shorter immunity [7].  
 
Transmission of C. trachomatis within a sexual partnership depends on the 
infectiousness of the infected person and their partner’s susceptibility. These 
characteristics are modeled in terms of the chlamydial load within infected 
individuals. Infectiousness is directly related to the within-host chlamydial load while 
susceptibility is measured by the minimum chlamydial load required to infect, which 
we define as the critical load. Potential vaccines may provide protection to uninfected 
individuals directly by increasing their critical load and/or indirectly by changing the 
chlamydial load within vaccinated individuals who become infected. Full protection 
occurs if the critical load increases to a value greater than the peak load of an infected 
individual; otherwise a vaccine is only partially protective. 
 
In our model males and females are only vaccinated before sexual debut. Vaccinated 
individuals are given different parameter values for their critical load, mean IFU 
doubling time, peak IFU load, mean IFU half-life, and duration of immunity. These 
parameters specify the properties of a vaccine and for a vaccinated person their value 
is fixed until the vaccine wanes.  The impact of vaccines is investigated by 
independently changing one parameter at a time for vaccinated individuals. 
 
The model is implemented using Matlab® R2008a with each simulation tracking the 
dynamic sexual network and chlamydial transmission over 70 years. We simulate 
various vaccine interventions. Vaccination is introduced at 50 years and continued 
until the end of each simulation. Each parameter set and vaccine regime is run 10 
times; to compare different vaccine properties and intervention strategies we took the 
median trajectory of the 10 simulations.  
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Results 
 
How long would it take to eradicate sexually transmitted Chlamydia with an 
effective vaccine? 
When there is no vaccination, all simulations show a stochastically oscillating 
prevalence ranging from 3-6% with median ~4.5% [IQR 4.1-4.9%] (Fig. 1a). The 
median prevalence of these simulations was chosen as the baseline for comparison 
with other scenarios. Our simulations reveal that an ongoing vaccination campaign 
using a completely protective vaccine with 100% coverage of individuals before 
sexual debut results in a declining epidemic and theoretical elimination within 15-20 
years (Fig. 1a). There would be a noticeable decrease in prevalence a few years post 
vaccine introduction and, despite stochastic oscillations, all simulations reach zero 
prevalence at a similar time (median 16.9 years; IQR 16.3-17.6 years) (Fig. 1a).  
 
Vaccines that wane after a finite duration 
Vaccines that wane in their protective immunity over time can still have a large 
impact with a noticeable reduction in prevalence even if the vaccine is effective for 
just one year (Fig. 1b). In order for a vaccine to eliminate a Chlamydia epidemic it 
would need to confer immunity for around 10 years, in which case eradication would 
take more than 20 years (Fig. 1b). A vaccine that is effective for at least ten years 
should be a goal for vaccine developers; if administered prior to sexual debut then 
adolescents are covered for the period in which they are at greatest risk of acquiring 
infection [15]. 
 
The impact of vaccine coverage rates 
If sub-optimal coverage is achieved then fully protective vaccines obviously have less 
impact (Fig. 2a). In such cases, targeting coverage can be beneficial. For example, 
vaccinating 50% of males and females before sexual debut (Fig. 2a, red line) appears 
to have less effect than vaccinating 100% of females (Fig. 2a, blue line) even though 
the same number of people are vaccinated. Figure 2b shows the incidence of PID in 
unvaccinated females according to the same coverage scenarios shown in Fig. 2a. 
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These results show a direct relationship between the prevalence of Chlamydia 
infections and the incidence of PID. Vaccinating 100% of females  before sexual 
debut (Fig. 2b, blue line) has a greater affect on PID incidence than vaccinating 50% 
of males and females (Fig. 2a, red line) suggesting that vaccination strategies should 
concentrate on females whilst also vaccinating males if feasible.  
 
The impact of partially protective vaccines 
Partially protective vaccines may be unable to eradicate Chlamydia epidemics even 
with 100% coverage (Fig. 3). The attainable critical IFU load, below which infection 
cannot occur, is highly important. Even a small increase in the critical load can greatly 
reduce the prevalence and incidence of Chlamydia infections (Fig. 3). While 
increasing the critical load from 500 IFUs to 103 IFUs in vaccinated individuals has 
no observable effect, increasing it to 104 IFUs (3log10 from the peak load of 107 IFUs) 
leads to a small decline in the Chlamydia prevalence to under 4% twenty years post 
vaccine introduction. This decline shows a slow continual rate of decrease that could 
result in the elimination of the epidemic over a large timescale but is more likely to 
converge to a lower endemic level. Each order of magnitude increase in the critical 
load produces a faster decrease in prevalence. When the critical load is 1/10th of the 
peak load (Fig. 3, purple line) the epidemic appears to be converging to zero 
prevalence with elimination greater than 20 years post vaccine introduction, showing 
that it is still possible to eliminate a Chlamydia epidemic with a partially effective 
vaccine. Clearly, the critical load induced by a vaccine is the key determinant of the 
epidemiological impact and whether eradication is possible. Around the peak of 
infection a Chlamydia-infected person remains highly infectious to someone 
vaccinated with an imperfect vaccine. While increasing the critical load has no effect 
on the duration of infection, it reduces the time that an infected person is infectious to 
a vaccinated uninfected partner. This highlights the large gain that is possible by 
decreasing the duration of infectiousness.  
 
Vaccines that alter infection course in infected people  
We investigated the effect of imperfect vaccines that have no preventative effect but 
alter the duration of infectiousness, the duration of infection, or the peak IFU within 
vaccinated individuals who become infected. We found that increasing the doubling 
time had no significant effect on the prevalence (Fig. 4a). This is not unexpected as 
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the time to reach the peak load is only a small proportion of the overall infection time. 
It is likely that changing the doubling time affects other characteristics of the 
chlamydial load, such as the peak IFU level. Decreasing the peak load within 
vaccinated individuals who have become infected greatly decreases the prevalence 
and can potentially eliminate an epidemic (Fig. 4b). A reduction in the peak load to a 
value less than 104 IFUs (a reduction of 3log10 (99.9%) from the unvaccinated peak 
load) could eradicate an epidemic in ~20 years (Fig. 4b). A similar result is achieved 
by reducing the peak load by 2log10 IFUs (99%), with a slightly longer time to 
eradication (Fig. 4b, red line). Reducing the peak load by 90% (to 1log10 from the 
unvaccinated peak IFU level) results in a slower decline in the epidemic, with a 
prevalence of ~2.5% after 20 years of vaccination. In contrast, protective vaccines that 
increase the critical load to a level 1log10 from the peak load theoretically eliminate an 
epidemic in less than 20 years (Fig. 2). Decreasing the infection peak load to 1/10th of 
its original value has a much smaller effect than increasing the critical load in a 
susceptible person to 1/10th of the peak value. This is due to the respective decreases 
in the duration of infectiousness (76% for increasing the critical load as opposed to 
23% for the reduction in the peak load).  
 
The impact of vaccines that decrease the half-life of the chlamydial load in infected 
individuals is shown in Figure 4c. While minor reductions (10%) in the half-life have 
little effect on an epidemic, reducing the half-life to less than 1/10th the value of the 
unvaccinated case a vaccine can theoretically eliminate an epidemic ~20 years post 
vaccine introduction. For vaccines that reduce the half-life by 90%, both the infection 
duration and duration of infectiousness are substantially reduced (by almost 90%, to 
47 days and 35 days respectively). 
 
The relative impact of each simulated vaccine on Chlamydia incidence and PID cases 
is shown in Figure 5. Maximum reduction in Chlamydia incidence and PID cases will 
obviously be achieved with 100% protective vaccines with 100% coverage. However, 
partially effective vaccines can still have a substantial effect on Chlamydia epidemics 
with vaccines that increase the critical load to ~1/10th of the peak level, decrease the 
peak load by ~3log10 (99.9%), or decrease the duration of infection by ~90% having 
similar effects.  Similar relative impacts could be expected between Chlamydia 
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incidence and the number of PID cases for each type of vaccine, except for vaccines 
that reduce the duration of infection (Fig. 5).    
 
We also simulated the potential epidemiological effect of Chlamydia vaccines that 
neither protect against acquiring infection nor change the infectiousness of infected 
people but increase the duration of immunity after clearance. We found that such 
vaccines would likely have only modest impacts on Chlamydia prevalence (Fig. 4d).  
 
 
Discussion 
 
What constitutes a fully protective immune response against genital Chlamydia 
infection remains unknown. However, evidence from animal models and limited 
human studies suggests a strong IFN-mediated Th1 response and a strong antibody 
response eliciting neutralizing antibodies in mucosal secretions are required for 
protective immunity [8]. Interferon-mediated mechanisms of protection are believed 
to be essential for limiting infection, whilst adoptive transfer of monoclonal 
antibodies against surface antigens (such as MOMP) can also limit infection in animal 
models [16]. A strong humoral response is also essential for effective recall immunity 
against secondary infections in animal models [17]. Therefore, most studies in animal 
models measure a variety of biomarkers including cytokines associated with Th1 (IL-
12, IFN) and Th2 (IL-4 and IL-10) responses, inflammatory cytokines such as TNF 
as well as neutralizing antibody in mucosal secretions. These biomarkers should be 
used to evaluate human vaccine trial outcomes, where it will be essential to monitor 
local mucosal responses at the site of infection, using cells obtained by cervical 
cytobrush techniques [18] and evaluating antibody responses in cervicovaginal 
secretions.  The choice of antigen is also an important factor in determining the 
success of a potential vaccine. Most studies to date have used MOMP, however, 
protection induced by MOMP is serovar-specific and short-lived making it unlikely 
that a vaccine based on MOMP alone will be effective. Recently, numerous novel 
chlamydial antigens have been identified that elicit partial immunity against multiple 
serovars of C. trachomatis in animal models [19-21]. Combinations of these antigens, 
administered as a multi-subunit vaccine may provide the best means of eliciting 
Comment [R1]: Can we cut some these 
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protective immunity. Currently, combinations that are effective in animal models are 
being identified prior to testing in human subjects.  
 
We have shown that if a fully protective vaccine was available, Chlamydia epidemics 
could be eradicated within 20 years. Unsurprisingly, greater vaccine coverage results 
in greater epidemiological outcomes. However, targeting 100% of one gender 
(females) is likely to have a greater epidemiological impact than administering 
vaccines to 50% of both genders. If lifelong sterilizing immunity cannot be attained 
then a Chlamydia vaccine would need to be effective for at least ten years for 
population-level eradication to become possible. Partially protective vaccines that 
increase the infectious threshold required for transmission can still be highly 
beneficial, although they would need to increase the critical load to ~1-2log10 from the 
peak load. Similarly, albeit not as effective, vaccines that reduce the peak load or the 
duration of infection in infected individuals can also have substantial population-level 
impacts. Our model suggests that Chlamydia vaccines can successfully control 
epidemics if they substantially reduce the time that infected people are infectious to 
susceptible people. Thus, microbiologists developing candidate vaccines should focus 
on vaccines that protect individuals by raising the infectiousness threshold and 
secondarily reduces the peak load and duration of infection of vaccinated individuals 
that become infected.  
 
There is concern that partial immunity could result in vaccine immunopathology. 
Early attempts at developing chlamydial vaccines were sometimes plagued by 
worsened immunopathology in individuals who had either been reinfected with 
Chlamydia or with a crude, whole organism vaccine after clearing a previous 
infection. However, it has now been demonstrated that the major contributor to the 
development of the observed immunopathology in chlamydial infections is likely to 
be the high homology that exists between human and chlamydial heat shock 60 
proteins [22-24]. Therefore, current vaccines aim to overcome this by only using 
purified recombinant proteins and screening the vaccine proteins against the human 
proteome and eliminating any targets that have even low levels of homology. 
Consequently, current chlamydial vaccines should generally be safe and should not 
cause an enhanced immunopathological reaction. Of course, safety studies are 
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necessary in early phases of clinical trials. But there is reason to believe that a 
chlamydial vaccine that was partially protective could be used safely. 
 
Although we decoupled vaccine properties in our analysis, they are unlikely to be 
completely independent. For example, vaccines could have both a protective effect 
and change the chlamydial load profile within infected individuals; such vaccines 
would be even more beneficial in controlling Chlamydia epidemics and reducing PID 
incidence. In our study we assumed that the probability of developing PID is constant 
over the course of an infection. If developing PID depends on the chlamydial load 
then a vaccine which reduces the peak load is likely to be the most beneficial. 
Similarly, if PID depends on the duration of infection then vaccines that reduce this 
time will have an even greater effect (Fig. 5). While immunity is possibly very 
important to Chlamydia epidemiology [7] and is included in our model, we did not 
investigate sensitivity to the duration of immunity. Although the average rate of 
sexual partner acquisition changes with age, we assumed homogeneous mixing with 
an average number of partners (Table 1). Another limitation of our analysis is that the 
relationship between chlamydial load and the probability of transmission is unknown. 
Various studies have reported transmission estimates: Quinn et al. [25] used a cross-
sectional study of sexual partnerships to estimate transmission probabilities from 
males-to-females and females-to-males over a partnership and found no significant 
differences (at 68% transmission frequencies); Viscidi et al. [26] used cell culture and 
PCR to analyze the level of Chlamydia infection in sexual partners of Chlamydia-
infected men and women and found transmission rates over the partnerships of 45-
75%. Other transmission studies [27-29] have estimated similar transmission rates, in 
the range of 25-40% of male sexual partners of Chlamydia-infected women and 40-
60% of female sexual partners of Chlamydia-infected men. No study has investigated 
the relationship between chlamydial load and transmission risk and no estimates of 
transmission risk have been based on longitudinal studies. Such a relationship has 
been investigated for HIV [30, 31]. In the absence of other data, we assumed a similar 
relationship exists for Chlamydia but we calibrated the association to reflect the 
different overall transmission probability of Chlamydia.  
  
Vaccination could be substantially more effective than other biomedical interventions 
in controlling Chlamydia epidemics. The best public health intervention that is 
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currently available is increasing the rate of screening and treating infected cases. 
Previously we estimated the relative reduction in population prevalence that could be 
attained with different screening coverage levels, targeted at different populations 
groups [32]. We showed that an 80% reduction in prevalence could be achieved after 
10 years of a screening intervention if 30% of all individuals younger than 30 years of 
age are tested and treated for Chlamydia each year [32]. This relative reduction in 
prevalence could not be achieved if teenagers are targeted for screening, even with 
100% coverage [32]. However, 80% reduction in prevalence could be obtained if a 
protective vaccine was administered to adolescents prior to sexual debut (Fig. 1a).  
 
Our current study sheds light on vaccine development. It has been suggested that an 
effective chlamydial vaccine will need to produce sterilizing immunity. Our study 
shows that a vaccine does not need to achieve sterilizing immunity to have an effect 
on the prevalence and incidence of infection. Even moderate vaccine-induced 
reductions in peak load and duration of infection can have major effects on Chlamydia 
epidemiology. This suggests that parameters commonly measured in animal models 
of infection (e.g., the ID50, duration of bacterial shedding, and amount of Chlamydia 
shed during an infection) are valid for the design of human vaccines and can be 
evaluated using our current model in terms of the potential population level impact on 
human infections. Our modeling approach can therefore be used to evaluate the results 
and impact of vaccination studies using new adjuvants and antigens and to guide 
future animal studies to achieve significant levels of protection in human populations.  
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Table:  Model parameters and values for the baseline case of no vaccination. 
Symbol Description Value/Range  Reference 
Sexual behavior parameters  
mina  Minimum age of sexually debut 13 years ¶[33] 
min ba   Average age of sexual debut 17 years ¶[33] 
maxa  Average age of departure from sexually 
active population (in terms of choosing new 
sexual partners) 
50 years 
¶[33] 
r
sf  Average number of sex acts per regular 
(long-term) partnership per week 
1.75 
 
[34] 
c
sf  Average number of sex acts per short-term 
partnership per week 3 
[34, 35] 
c
cp  Proportion of sex acts in a short-term 
partnership in which a condom is used 30% 
[35, 36] 
r
cp  Proportion of sex acts in a regular 
partnership where a condom is used 
c
c
r
c pp )1( 
 
[37] 
  Relative reduction in condom use for 
regular partnerships compared with short 
term partnerships 
0.9 
ε Per-act effectiveness of condoms in 
preventing transmission 90% 
[37, 38] 
corep  Percentage of people who may have 
concurrent sexual partnerships (we define 
as core group) 
5% 
¶ [39] 
rp  The probability that a newly formed sexual 
partnership becomes a regular partnership 0.4 
¶ [34, 39] 
rt  The average time duration of a regular 
(long-term) partnership 8 years 
¶ [34, 40] 
ct  The average time duration of a short term 
partnership 14 days 
¶ [34, 40] 
at  The average time duration between 
partnerships for non-core group people 315 days 
¶ [34, 40] 
c
at  The average time duration between 
partnerships for core group people 21
c
a at t   ¶ 
i
pp  Probability that a core group 
person is available to form 
another partnership if they 
currently have: 
no partners 0
pp = 1 ¶ 
1 partner 1
pp = 0.5 
2 partners 2
pp = 0.25 
3 partners 3
pp = 0 
Chlamydial load parameters 
pl  The peak chlamydial load in an infected 
individual (number of bacterial copies) 10
7 ‡ 
 The initial chlamydial load in a newly 
infected individual 100 
‡ 
0l
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 The average doubling time of chlamydial 
load during the early expansion phase at the 
onset of infection 
6 hours 
 
‡ 
Person-to-person variability in the doubling 
time ± 2.4 hours 
 Chlamydial load half-life following the 
peak load 21 days 
‡ 
Person-to-person variability in the half-life ± 10 days 
cl  The minimum chlamydial load required to 
be infectious (number of bacterial copies) 500 
‡ 
lmin The chlamydial load at which infection has 
‘cleared’ 10 
¶ 
βp Transmission probability per act at the peak 
chlamydial load  0.45 
† 
Transmission probability per act for any 
given chlamydial load level § 
Clinical parameters 
 
Probability that a chlamydial infection 
becomes symptomatic 0.25 
[6, 12] 
ap  Probability that an infection in a female 
ascends to the upper genital tract 0.2 
[13] 
 The duration of immunity after natural 
recovery from infection before which an 
individual is susceptible to re-infection. 45days 
[41, 42] 
 Person-to-person variability in the duration 
of immunity following natural recovery of 
infection ± 15 days 
 The duration of immunity for a person that 
has recovered from infection through 
treatment  
 
days 
[7, 43] 
Person-to-person variability in the duration 
of immunity following recovery due to 
treatment ± 53 days 
s
tp  Percentage of people with symptoms that 
seek treatment 0.8 
[44, 45] 
  Test sensitivity (proportion of infected that 
test positively) 85% [46, 47] 
 The time after symptoms arise that a person 
is likely to seek treatment. Uniformly 
distributed between 1 and mst  
m
st1  days 
[46, 48] 
 The maximum time that it takes for a 
symptomatic person to seek treatment 10 days 
[46, 48] 
nt
et
ht
tt nt tt 5
s
ip
st
m
st
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a
tf  The probability per year that a female with 
an asymptomatic infection is tested for 
Chlamydia 
0.04 
[44, 45] 
 
The probability per year that a male with an 
asymptomatic infection is tested for 
Chlamydia 
0.025 
[44, 45] 
¶: Experimental variable based on our assumption. The sexual behavior parameters 
are calibrated so that the cumulative distribution of the lifetime number of partners 
matches those obtained from sexual behavior surveys  (see Fig. S3 in the 
Supplementary Material).  
‡: The chlamydial load parameters are based on well-documented studies in animal 
models [41, 49], with the exception of the half-life of the chlamydial load. Since it is 
thought that humans are infected for 9-18 months on average in the absence of 
treatment [50], we assume a half-life that provides duration of infection of ~14 
months. The chlamydial load function is described in the Appendix.  
†:  This is the per act transmission probability for someone with a chlamydial load of 
pl . This is set to calibrate the model such that the median prevalence of Chlamydia in 
the population is in the specified range of 4-5%.  
§: The probability of transmission per act, β, is dependent on the chlamydial load 
within an infected person at the time of sexual intercourse. This relationship is 
described in detail in the Supplementary material. 
 
a
tm
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Figure Legends: 
 
Figure 1: (a) The prevalence of Chlamydia in a heterosexual population versus time, 
indicating the impact of a 100% protective vaccine. All model simulations are shown 
for 100% vaccine coverage before sexual debut (green with median in black) in 
comparison to the baseline scenario of no vaccine (red with median in blue). (b) 
Prevalence of Chlamydia as a function of time for vaccines that wane after a finite 
duration of 1 year, 5 years, and 10 years. 
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Figure 2:  The impact of different male and female coverage rates before sexual 
debut on (a) Chlamydia prevalence and (b) PID incidence for a 100% protective 
vaccine. Results are median values for ten model simulations. The results for 100% 
coverage of males and females are the same as in Fig. 1. 
 
Figure 3: The prevalence of Chlamydia after the introduction of partially protective 
vaccines with 100% coverage of incoming sexually active individuals. Each curve 
shows the median prevalence for 10 simulations of the same parameter set. The 
vaccine critical load is measured relative to the peak load in an infected person. In the 
no vaccine case the critical load is 4.3log10 from the peak load. Here, the duration of 
infectiousness is 306 days (no vaccine), 284 days (lc=103), 213 days (lc=104), 143 
days (lc=105), 72 days (lc=106), and 0 days (lc=lp=107). The blue and black lines are 
the same as in Fig. 1. 
 
Figure 4: Prevalence of Chlamydia versus time, indicating the impact of vaccines that 
change the chlamydial load profile in a vaccinated person who becomes infected by 
(a) increasing the doubling time, (b) decreasing the peak load, and (c) decreasing the 
half-life. In each figure the blue curve is the median curve for the no vaccine case in 
Fig. 1a. (d) Prevalence of Chlamydia as a function of time, indicating the impact of 
vaccines that increase the duration of natural immunity post infection by a factor of 2, 
5, and 10. 
 
Figure 5: Percentage decrease in the total number of Chlamydia (red) and PID (blue) 
cases 20 years post vaccine introduction for each vaccine strategy shown in Figs. 1-4. 
Results were obtained by calculating the median total number of infections and PID 
cases for the 10 simulations of each vaccine. The decreases were then calculated by 
comparing the median values for the vaccine to the median incidence and PID cases 
when no vaccine is introduced. 
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